Lung cancer remains the leading cause of cancer-related death in the United States among both men and women. According to data from the Surveillance, Epidemiology, and End Results (SEER) Program, the annual incidence rate is approximately 47.8 new cases per 100,000 persons, with a mortality rate of 31.5 per 100,000. These figures translate into tens of thousands of lives lost each year and highlight the substantial public health burden of this disease.
While researchers have made significant strides in cancer prevention and treatment overall, lung cancer continues to exact a heavy toll, particularly in older populations. Nearly 96% of lung cancer deaths occur in individuals aged 55 and older, with about three-quarters in those over age 65.
Related CE course for physicians: Lung Cancer, 3rd Edition
Positive trends
One of the most impactful trends over the past three decades has been the decline in smoking rates. This corresponds with a decrease in lung cancer mortality, particularly among men. Since the early 1990s, smoking cessation efforts have lead to a 30% plunge in cancer death rates overall in the United States.
Although tobacco use remains the primary risk factor, accounting for approximately 80% to 90% of all lung cancer cases worldwide, healthcare providers have noted other risk factors. Secondhand smoke remains a significant concern, particularly for nonsmoking spouses and children living with smokers. Radon gas exposure, often occurring in homes with poor ventilation or foundation cracks, is another well-established carcinogen.
Researchers have linked occupational exposure to substances such as asbestos, arsenic, diesel exhaust, and silica to an increased risk. These are common in the construction, mining, and manufacturing industries.
Development, clinical manifestations, and diagnostic evaluation of lung cancer
The development of lung cancer begins at the cellular level, typically in the epithelial lining of the bronchi or alveoli. Lung cancer is broadly classified into two major types:
- Non-small cell lung cancer (NSCLC), which accounts for approximately 85% of cases. NSCLC includes subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
- Small cell lung cancer (SCLC), comprising about 15%.
Adenocarcinoma is the most common type, particularly in nonsmokers. Specific genetic mutations such as EGFR, ALK, or ROS1 often drive these types of cancer. SCLC, in contrast, has an aggressive nature and early metastatic spread. Heavy smoking is a common cause of SCLC
Clinical manifestations, symptoms, and diagnosis
Lung cancer presents a range of clinical manifestations that vary based on the disease’s stage and type. In the early stages, many individuals may not exhibit any symptoms, which can lead to delays in diagnosis. As the disease advances, common symptoms often include a persistent cough, chest pain, shortness of breath, and hemoptysis. In later stages, systemic symptoms such as unexplained weight loss, fatigue, and loss of appetite may also become prevalent.
Additionally, patients with SCLC may experience paraneoplastic syndromes, such as syndrome of inappropriate antidiuretic hormone secretion or Lambert-Eaton myasthenic syndrome. In cases of metastatic lung cancer, patients may experience further symptoms depending on the affected organs, such as bone pain and neurological deficits.
Diagnostic procedures
The diagnostic process for lung cancer generally starts with imaging studies. Low-dose computed tomography is a key method for lung cancer screening. High-risk groups include those aged 50 to 80 with a history of smoking equivalent to 20 pack-years or more.
When screening or clinical imaging reveals abnormalities, a provider may order further evaluation using high-resolution CT scans and positron emission tomography scans. When a provider suspects metastasis, technicians perform magnetic resonance imaging of the brain to assess the potential spread of the disease.
Confirming a lung cancer diagnosis and identifying the histologic subtype are critical steps, often achieved through tissue biopsy. Sputum samples may be appropriate in detecting squamous cell cancers that arise from the major airways of the lung.
However, more commonly, providers collect biopsy samples using methods such as bronchoscopy, CT-guided percutaneous needle biopsy, or surgical techniques. Following diagnosis, molecular testing is crucial for identifying targetable genetic mutations that can guide treatment decisions.
Additionally, laboratory tests, including blood counts, assessments of liver and kidney function, and lactate dehydrogenase levels, help evaluate the overall health of the patient. Pulmonary function tests are particularly vital for patients being evaluated for potential surgical intervention. Lastly, accurate staging using the TNM system for non-small cell lung cancer (NSCLC) or the limited/extensive classification for SCLC is crucial in devising an appropriate treatment strategy.
Treatment options for NSCLC and SCLC
Treatment options vary significantly between NSCLC and SCLC and are largely determined by the stage of disease at diagnosis. In early-stage NSCLC (stage I or II), surgical resection offers the best chance for cure, particularly lobectomy or pneumonectomy with curative intent.
For patients who are not candidates for surgery due to other health conditions, stereotactic body radiation therapy may be an option. This delivers high-dose radiation with remarkable precision. Adjuvant chemotherapy, usually platinum-based, is often used to reduce the risk of recurrence. In select cases, immunotherapy may be added as adjuvant treatment, particularly in patients with high PD-L1 expression.
Stage III NSCLC is typically managed with concurrent chemoradiation. It is followed by consolidation immunotherapy featuring agents like durvalumab. These have been associated with improved progression-free and overall survival rates.
In patients with actionable mutations, such as EGFR, targeted therapies like osimertinib may be used as adjuvant treatment after definitive therapy. For metastatic NSCLC (stage IV), systemic therapy is the mainstay. Immune checkpoint inhibitors such as pembrolizumab or atezolizumab are often used alone or in combination with chemotherapy for patients without driver mutations.
On the other hand, patients with specific genetic alterations, such as EGFR mutations, may benefit from targeted therapies like osimertinib. Those with ALK rearrangements may be treated with alectinib or lorlatinib. In patients with ROS1 fusions, entrectinib is a viable option.
Treatment options for SCLC
SCLC is characterized by rapid growth and early spread, typically necessitating treatment with chemotherapy and radiation. For limited-stage SCLC, the standard treatment regimen involves a combination of cisplatin or carboplatin with etoposide, alongside concurrent thoracic radiation. Prophylactic cranial irradiation is frequently recommended to mitigate the risk of brain metastases.
In cases of extensive-stage SCLC, systemic chemotherapy is combined with immunotherapy agents, like atezolizumab or durvalumab. Managing relapsed SCLC presents a significant challenge, often offering limited options beyond second-line chemotherapy or participation in clinical trials.
Psychosocial support for patients and families
Any cancer diagnosis often triggers profound emotional distress, anxiety, depression, and existential concerns. Access to psychological counseling, support groups, and mental health professionals is vital in addressing these emotional challenges. Clear and compassionate communication regarding diagnosis, treatment options, and prognosis empowers patients to participate actively in their decision-making process.
Additionally, social workers and patient navigators can assist with navigating financial difficulties, insurance processes, and logistical barriers to care, such as transportation or housing. It is also important to include families in care planning, offering them support services and bereavement counseling as necessary.
Conclusion
Lung cancer remains a significant health challenge in the United States. It is marked by high mortality rates and a complex interplay of genetic, environmental, and behavioral risk factors. While advancements in targeted therapy and immunotherapy have markedly improved outcomes for many patients, the importance of early detection, comprehensive care, and preventive measures cannot be overstated.
A multidisciplinary approach that integrates medical treatment, symptom management, psychosocial support, and public health initiatives provides the most effective strategy in mitigating the disease’s burden and enhancing the quality of life for those affected.
